Patents by Inventor Michael Lochrie

Michael Lochrie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ADENO-ASSOCIATED VIRUS CAPSID PROTEINS
    Publication number: 20240317813
    Abstract: The invention relates to novel adeno-associated virus (AAV) capsid proteins, AAV particles comprising a novel capsid protein, polynucleotides encoding these capsid proteins and AAV vectors expressing these capsid proteins. The invention also relates to methods of making the herein described AAV vectors expressing the novel capsid proteins of the invention and associated therapeutic uses of thereof.
    Type: Application
    Filed: May 28, 2024
    Publication date: September 26, 2024
    Applicant: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Peter Cameron COLOSI, Michael LOCHRIE, Robert NG
  • NOVEL ADENO-ASSOCIATED VIRUS CAPSID PROTEINS
    Publication number: 20230322864
    Abstract: The invention relates to novel adeno-associated virus (AAV) capsid proteins, AAV particles comprising a novel capsid protein, polynucleotides encoding these capsid proteins and AAV vectors expressing these capsid proteins. The invention also relates to methods of making the herein described AAV vectors expressing the novel capsid proteins of the invention and associated therapeutic uses of thereof.
    Type: Application
    Filed: December 8, 2022
    Publication date: October 12, 2023
    Applicant: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Peter Cameron COLOSI, Michael LOCHRIE, Robert NG
  • VIRUS-FREE CELL CULTURES
    Publication number: 20230075854
    Abstract: The invention is directed to methods of removing adventitious virus from cells and cell lines and virus-free cells and cell lines obtainable by such methods.
    Type: Application
    Filed: February 9, 2021
    Publication date: March 9, 2023
    Inventors: Michael LOCHRIE, Peter COLOSI, Barrie CARTER, Tomas CINEK
  • Adeno-associated virus capsid proteins
    Patent number: 11584780
    Abstract: The invention relates to novel adeno-associated virus (AAV) capsid proteins, AAV particles comprising a novel capsid protein, polynucleotides encoding these capsid proteins and AAV vectors expressing these capsid proteins. The invention also relates to methods of making the herein described AAV vectors expressing the novel capsid proteins of the invention and associated therapeutic uses of thereof.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: February 21, 2023
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Peter Cameron Colosi, Michael Lochrie, Robert Ng
  • NOVEL ADENO-ASSOCIATED VIRUS CAPSID PROTEINS
    Publication number: 20220402974
    Abstract: The invention relates to novel adeno-associated virus (AAV) capsid proteins, AAV particles comprising a novel capsid protein, polynucleotides encoding these capsid proteins and AAV vectors expressing these capsid proteins. The invention also relates to methods of making the herein described AAV vectors expressing the novel capsid proteins of the invention and associated therapeutic uses of thereof.
    Type: Application
    Filed: July 25, 2017
    Publication date: December 22, 2022
    Inventors: Peter Cameron Colosi, Michael LOCHRIE, Robert NG
  • IMPROVED LENTIVIRUSES FOR TRANSDUCTION OF HEMATOPOIETIC STEM CELLS
    Publication number: 20210139932
    Abstract: Recombinant viruses, comprising a lentiviral vector carrying a heterologous transgene, packaged in an envelope containing at least one heterologous envelope protein, are described. Also described are methods of producing these recombinant viruses and methods of using these viruses to deliver genes to selected target cells. These recombinant viruses are particularly useful for transducing a hematopoietic stem cells, in particular CD34+ cells.
    Type: Application
    Filed: May 3, 2018
    Publication date: May 13, 2021
    Inventors: Michael Lochrie, Wes Yonemoto, Ramya Ankata, Jac Michael
  • Nucleic Acid Ligands Which Bind to Hepatocyte Growth Factor/Scatter Factor (HGF/SF) or its Receptor c-met
    Publication number: 20090075922
    Abstract: The invention provides nucleic acid ligands to hepatocyte growth factor/scatter factor (HGF) and its receptor c-met. The nucleic acid ligands of the instant invention are isolated using the SELEX method. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the invention are useful as diagnostic and therapeutic agents for diseases in which elevated HGF and c-met activity are causative factors.
    Type: Application
    Filed: May 14, 2007
    Publication date: March 19, 2009
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Ross Rabin, Michael Lochrie, Nebojsa Janjic, Larry Gold
  • AAV virions with decreased immunoreactivity and uses therefor
    Publication number: 20080008690
    Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.
    Type: Application
    Filed: July 9, 2007
    Publication date: January 10, 2008
    Inventors: Alejandra Arbetman, Peter Colosi, Michael Lochrie, Richard Surosky
  • Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
    Publication number: 20060148748
    Abstract: The invention provides nucleic acid ligands to hepatocyte growth factor/scatter factor (HGF) and its receptor c-met. The nucleic acid ligands of the instant invention are isolated using the SELEX method. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the invention are useful as diagnostic and therapeutic agents for diseases in which elevated HGF and c-met activity are causative factors.
    Type: Application
    Filed: December 19, 2005
    Publication date: July 6, 2006
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Ross Rabin, Michael Lochrie, Nebojsa Janjic, Larry Gold
  • High affinity TGFbeta nucleic acid ligands and inhibitors
    Publication number: 20060084797
    Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGF?2. Included in the invention are specific RNA ligands to TGF?2 identified by the SELEX method. Also included are RNA ligands that inhibit the interaction of TGF?2 with its receptor.
    Type: Application
    Filed: November 23, 2005
    Publication date: April 20, 2006
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Nikos Pagratis, Michael Lochrie, Larry Gold
  • AAV virions with decreased immunoreactivity and uses therefor
    Publication number: 20060051333
    Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.
    Type: Application
    Filed: June 21, 2004
    Publication date: March 9, 2006
    Inventors: Alejandra Arbetman, Peter Colosi, Michael Lochrie, Richard Surosky
  • AAV vectors for gene delivery to the lung
    Publication number: 20060018841
    Abstract: Methods of making and using recombinant AAV vectors and virions for gene delivery to the lung are described. The recombinant AAV virions are derived from caprine AAV and bovine AAV, both of which display tropism for lung tissue.
    Type: Application
    Filed: June 2, 2005
    Publication date: January 26, 2006
    Applicant: Avigen, Inc.
    Inventors: Alejandra Arbetman, Michael Lochrie
  • High affinity TGFbeta nucleic acid ligands and inhibitors
    Publication number: 20040258656
    Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGF&bgr;2. Included in the invention are specific RNA ligands to TGF&bgr;2 identified by the SELEX method. Also included are RNA ligands that inhibit the interaction of TGF&bgr;2 with its receptor.
    Type: Application
    Filed: March 30, 2004
    Publication date: December 23, 2004
    Inventors: Nikos Pagratis, Michael Lochrie, Larry Gold
  • High affinity TGF&bgr; nucleic acid ligands and inhibitors
    Patent number: 6713616
    Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGF&bgr;2. Included in the invention are specific RNA ligands to TGF&bgr;2 identified by the SELEX method. Also included are RNA ligands that inhibit the interaction of TGF&bgr;2 with its receptor.
    Type: Grant
    Filed: February 23, 2001
    Date of Patent: March 30, 2004
    Assignee: Gilead Sciences, Inc.
    Inventors: Nikos Pagratis, Michael Lochrie, Larry Gold
  • High affinity TGFbeta nucleic acid ligands and inhibitors
    Publication number: 20030064943
    Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGF&bgr;2. Included in the invention are specific RNA ligands to TGF&bgr;2 identified by the SELEX method. Also included are RNA ligands that inhibit the interaction of TGF&bgr;2 with its receptor.
    Type: Application
    Filed: February 23, 2001
    Publication date: April 3, 2003
    Inventors: Nikos Pagratis, Michael Lochrie, Larry Gold
  • Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
    Publication number: 20030049644
    Abstract: The invention provides nucleic acid ligands to hepatocyte growth factor/scatter factor (HGF) and its receptor c-met. The nucleic acid ligands of the instant invention are isolated using the SELEX method. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the invention are useful as diagnostic and therapeutic agents for diseases in which elevated HGF and c-met activity are causative factors.
    Type: Application
    Filed: February 4, 2002
    Publication date: March 13, 2003
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Ross Rabin, Michael Lochrie, Nebojsa Janjic, Larry Gold
  • High affinity TGf&bgr; nucleic acid ligands and inhibitors
    Patent number: 6346611
    Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGF&bgr;2. Included in the invention are specific RNA ligands to TGF&bgr;2 identified by the SELEX method. Also included are RNA ligands that inhibit the interaction of TGF&bgr;2 with its receptor.
    Type: Grant
    Filed: July 29, 1999
    Date of Patent: February 12, 2002
    Assignee: Gilead Sciences, Inc.
    Inventors: Nikos Pagratis, Michael Lochrie, Larry Gold
  • Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
    Patent number: 6344321
    Abstract: The invention provides nucleic acid ligands to hepatocyte growth factor/scatter factor (HGF) and its receptor c-met. The nucleic acid ligands of the instant invention are isolated using the SELEX method. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the invention are useful as diagnostic and therapeutic agents for diseases in which elevated HGF and c-met activity are causative factors.
    Type: Grant
    Filed: July 29, 1999
    Date of Patent: February 5, 2002
    Assignee: Gilead Sciences, Inc.
    Inventors: Ross Rabin, Michael Lochrie, Nebojsa Janjic, Larry Gold